Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
Author:
Affiliation:
1. Bristol-Myers Squibb; Princeton NJ USA
2. ImmunoGen, Inc.; Waltham MA USA
3. AbbVie Stemcentrx LLC; South San Francisco CA USA
Funder
Bristol-Myers Squibb
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference100 articles.
1. Cell killing by antibody-drug conjugates;Kovtun;Cancer Lett,2007
2. Antibody-drug conjugates: current status and future directions;Perez;Drug Discov Today,2014
3. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets;Clynes;Nat Med,2000
4. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer;Junttila;Breast Cancer Res Treat,2011
5. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity;Jedema;Leukemia,2004
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data;European Journal of Cancer;2023-09
2. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy;Pharmaceutics;2023-07-26
3. The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics;Chemical Reviews;2023-05-15
4. Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer;Cell Death & Disease;2023-04-29
5. Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy;Cancers;2023-04-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3